Immune Design Corp (IMDZ.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|77||2013||Independent Chairman of the Board|
|58||2011||President, Chief Executive Officer, Director|
|47||2015||Executive Vice President, Strategy & Finance|
|48||2016||Senior Vice President, Clinical Development, and Chief Medical Officer|
|54||2013||Chief Scientific Officer|
- BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design
- BRIEF-Immune Design reports Q3 loss per share of $0.52
- BRIEF-Immune Design prices offering of 19.5 million shares at $4.10 per share
- BRIEF-Immune Design proposes public offering of common stock
- BRIEF-Immune design announces G100’s receipt of orphan drug designation by EMA